Events

LAVA Therapeutics Presents a Corporate Overview at 39th Annual J.P. Morgan Healthcare Conference.

Want to learn more about how engaging T-cells via bispecific antibodies can change the course of cancer treatment? LAVA’s EVP, Head of R&D Paul Parren, PhD is chairing the ‘Bispecific T cell Engagers’ session at the Antibody Engineering and Therapeutics conference on Monday, December 14. LAVA’s CSO, and Hans van der Vliet, MD, PhD, will be on the panel. More information.

Lava’s EVP and Head of R&D, Paul Parren, PhD, and CSO, Hans van der Vliet, MD, PhD, will speak at the 12th Annual PEGS Europe Conference on Nov 11.

9am – Paul Parren – Next-Generation T Cell Engagers
9:20am – Hans van derVliet – Bispecific γδ-T Cell Engagers for Cancer Immunotherapy.
11:55am – Paul Parren – Panel Discussion: Gamma Delta T Cell Therapy

Lava’s EVP and Head of R&D, Paul Parren, PhD, spoke about the use of antibody drug conjugates in BCa. Learn more about the power of antibodies here

Lava’s EVP and Head of R&D, Paul Parren, PhD, will give an opening keynote address at the 8th Antibody Industrial Symposium (AIS) Congress on November 23rd at 9am CET. More information about this event

Lava’s EVP and Head of R&D, Paul Parren, PhD, will speak at the European Antibody Congress 2020. More information about this event.